TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06585891

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB0121-00-AB
Description: The CAP256J3LS bispecific antibody (bsAb) targets the V2-apex and CD4-binding sites of the HIV-1 envelope. It is composed of CAP256V2LS antibody with the light chain linked to the llama nanobody J3, which has broad CD4-binding site-directed neutralization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB0121-00-AB
Description: The CAP256J3LS bispecific antibody (bsAb) targets the V2-apex and CD4-binding sites of the HIV-1 envelope. It is composed of CAP256V2LS antibody with the light chain linked to the llama nanobody J3, which has broad CD4-binding site-directed neutralization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB0121-00-AB
Description: The CAP256J3LS bispecific antibody (bsAb) targets the V2-apex and CD4-binding sites of the HIV-1 envelope. It is composed of CAP256V2LS antibody with the light chain linked to the llama nanobody J3, which has broad CD4-binding site-directed neutralization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB0121-00-AB
Description: The CAP256J3LS bispecific antibody (bsAb) targets the V2-apex and CD4-binding sites of the HIV-1 envelope. It is composed of CAP256V2LS antibody with the light chain linked to the llama nanobody J3, which has broad CD4-binding site-directed neutralization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB0121-00-AB
Description: The CAP256J3LS bispecific antibody (bsAb) targets the V2-apex and CD4-binding sites of the HIV-1 envelope. It is composed of CAP256V2LS antibody with the light chain linked to the llama nanobody J3, which has broad CD4-binding site-directed neutralization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB0121-00-AB
Description: The CAP256J3LS bispecific antibody (bsAb) targets the V2-apex and CD4-binding sites of the HIV-1 envelope. It is composed of CAP256V2LS antibody with the light chain linked to the llama nanobody J3, which has broad CD4-binding site-directed neutralization.
Study: NCT05548764

Intervention type: PROCEDURE
Intervention: Prevention Bundles for SSIs
Description: 10 preoperative, intraoperative and postoperative bundles that aim to decrease SSIs rate after their implementation in patients that underwent abdominal surgery.
Study: NCT05414175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days
Study: NCT05913401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 20 minutes of supervised aerobic exercise on a treadmill prior to each TMS session

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video Watching
Description: 20 minutes of watching documentaries or educational videos prior to each TMS session
Study: NCT05125146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBTi
Description: See arm/group description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: See arm/group edescription
Study: NCT05905783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Solution for injection
Study: NCT05771675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40Mg Oral Tablet
Study: NCT06675461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gold Card Intervention
Description: A 4-session manualized intervention consisting of weekly scheduled 50-minute 1:1 sessions focused on psycho-education, here-and-now problem solving and safety planning. One of the sessions can involve a significant other to provide psychoeducation about the disorder and to facilitate support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Access to psychiatric assessment, medication review, and unscheduled sessions with allied health professionals using a drop-in model of care.
Study: NCT06627751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography Assisted Biopsy
Description: Undergo CT guided tumor Biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and saliva sample collection
Study: NCT06690307

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient controlled intravenous analgesia(PCIA)
Description: Patients will receive sulfentanil for PCIA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient controlled intravenous analgesia(PCIA)
Description: Patients will receive oxycodone for PCIA.
Study: NCT06711484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speak up traning program
Description: The intervention includes the training program to be applied to the experimental group. The aims and objectives of the training program, the training content and modules were prepared by the researcher in line with the needs analysis. The training program consists of four modules: Communication, Speaking UP, Patient Safety and Medical Error. Before the training program starts, the training booklet will be distributed to the experimental group participants. In the training, teaching techniques such as plain narration, question and answer, brainstorming, case study, case discussion, station technique, six thinking hats technique, video-based error scenario activity etc. will be used. The video activity to be used in the speak up session of the training program was created by recording the correct and incorrect scenarios of three patient safety errors by experienced actors.
Study: NCT06714981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Free Anaesthesia
Description: patients received opioid free anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid based Anesthesia
Description: patients received opioid based anesthesia
Study: NCT06716372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSiHy Silicone Hydrogel Soft Contact Lens
Description: The daily wear, daily disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Daily Silicone Hydrogel Contact Lenses (oB)
Description: The daily wear, daily disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
Study: NCT06712836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET097
Description: MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.
Study: NCT06710210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with a bioresorbable scaffold and drug-coated balloon(s)
Description: Hybrid PCI combining a magnesium-based sirolimus-eluting bioresorbable scaffold (Freesolve, Biotronik AG, Switzerland) and ≥1 paclitaxel-eluting drug-coated balloon(s) (Pantera Lux, Biotronik AG, Switzerland)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with drug-eluting stent(s)
Description: PCI with \>1 newer-generation drug-eluting stent (Orsiro Mission, Biotronik AG, Switzerland)
Study: NCT06719492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: 15 minutes of surgery specific nutrition education provided by a Registered Dietitian.
Study: NCT06717412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: Administered as an intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conbercept
Description: Administered as an intravitreal injection
Study: NCT06718023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic walking
Description: NW training sessions are conducted by a certified NW instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, each interval of 1 or 2 days, a total of 12 weeks. Participants used professional Nordic Pole.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training was conducted in the gym with progressively increasing resistance from 65% to 75% of the maximum weight (one-repetition maximum (1-RM)). Participants performed 10-13 repetitions of the exercise in one serie. The training was carried out in station form and consisted of 10-13 exercises. There were rest intervals of 60-90 seconds between exercises. As intended, the training was comprehensive, i.e. it affected the muscles of the arms, legs, torso, abdomen and chest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bungy Pump Exercises
Description: Buny Pump training sessions are conducted by a certified BP instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, , a total of 12 weeks. Participants used professional Bungy Pump Pole.
Study: NCT06718790

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Using menstrual cup
Description: In the prospective, randomized controlled study, two groups (Case = Menstrual cup, Control = Menstrual pad) will be randomly formed from individuals who volunteer to participate in the study and meet the inclusion criteria. All participants will be asked to answer the questions in the first interview questionnaire.~Women who will use menstrual cups will be trained on the use of the product and a menstrual cup will be provided for them to use. In the next stage, participants will be called by phone in the 1st, 2nd, 3rd and 6th menstrual cycles and asked to answer questions about their menstrual cup use by sharing an online form.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Using menstrual pads
Description: In the prospective, randomized controlled study, two groups (Case = Menstrual cup, Control = Menstrual pad) will be randomly formed from individuals who volunteer to participate in the study and meet the inclusion criteria. All participants will be asked to answer the questions in the first interview questionnaire. For women in the group who will use menstrual pads, the average number of pads they have used in their previous menstrual cycles will be asked and an appropriate number of menstrual pads will be provided. In the next stage, participants will be called by phone in the 1st, 2nd, 3rd, and 6th menstrual cycles and asked to answer questions about their menstrual pad use by sharing an online form.
Study: NCT06719193

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enhanced community-wide TB intervention
Description: Interventions in the intervention arms consist of the following key components:~1. an optimized national recommended set of interventions; such as the implementation of all types of contact investigation, targeted TB screening and diagnosis at key affected population, and optimized HIV screening and TPT for PLHIV;~2. intensive, active, and community-based HH screening and diagnosis of TB using combined TB screening (clinical and X-ray) and X-pert MTB/RIF, as indicated;~3. community-based enhanced TPT; and~4. community-based awareness creation and health education using the community social associations.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Routine TB program activities
Description: In the control arm, the standard of care will continue per the national guideline.
Study: NCT06715462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N0750
Description: N0750 caps + Cymbalta placebo caps + Lyrica placebo caps

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cymbalta®
Description: Cymbalta® caps + N0750 placebo caps + Lyrica placebo caps
Study: NCT04475991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc+Favipiravir+CT
Description: Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND Favipiravir tablets 200 mg. given orally for the first 7 days. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)
Study: NCT06715462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica®
Description: Lyrica® caps + N0750 placebo caps + Cymbalta placebo caps
Study: NCT06717243

Intervention type: DRUG
Intervention: Carboplatin/Cisplatin -Etoposide - Atezolizumab
Description: This intervention represents the standard-of-care first-line treatment regimen for extensive-stage small cell lung cancer (ES-SCLC). The regimen includes:~Carboplatin or Cisplatin: Platinum-based chemotherapeutic agents that cause DNA cross-linking, leading to tumor cell death.~Etoposide: A topoisomerase II inhibitor that prevents DNA replication and tumor growth.~Atezolizumab: A PD-L1 immune checkpoint inhibitor that enhances the immune system's ability to detect and destroy cancer cells.~This combination therapy is administered as part of routine clinical practice. The study does not investigate the efficacy or safety of these drugs but rather focuses on analyzing molecular changes in tumors, such as genomic and epigenetic alterations, to understand mechanisms of treatment resistance. Biospecimens are collected from patients during treatment and progression for detailed analysis.

Intervention type: DRUG
Intervention: Carboplatin/Cisplatin -Etoposide - Atezolizumab
Description: This intervention represents the standard-of-care first-line treatment regimen for extensive-stage small cell lung cancer (ES-SCLC). The regimen includes:~Carboplatin or Cisplatin: Platinum-based chemotherapeutic agents that cause DNA cross-linking, leading to tumor cell death.~Etoposide: A topoisomerase II inhibitor that prevents DNA replication and tumor growth.~Atezolizumab: A PD-L1 immune checkpoint inhibitor that enhances the immune system's ability to detect and destroy cancer cells.~This combination therapy is administered as part of routine clinical practice. The study does not investigate the efficacy or safety of these drugs but rather focuses on analyzing molecular changes in tumors, such as genomic and epigenetic alterations, to understand mechanisms of treatment resistance. Biospecimens are collected from patients during treatment and progression for detailed analysis.
Study: NCT06716996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated transcranial magnetic stimulation
Description: 20 sessions of repeated transcranial magnetic stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham treatment
Description: 20 sessions of sham treatment
Study: NCT06715527

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-Inositol and D-Chiro-Inositol (40:1)
Description: Myo-inositol and D-chiro-inositol (40:1 ratio), 2 grams (twice a day) for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myo-Inositol and D-Chiro-Inositol (3.6:1)
Description: Myo-inositol and D-chiro-inositol (3.6:1 ratio), 1.4 grams (once daily) for three months
Study: NCT06717282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual rehabilitation for ophthalmic compliance
Description: contextual, behavioral, and cognitive-based program for ophthalmic compliance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using contextual, behavioral, and cognitive-based stragegies to develop training programs
Description: Key Features of the Intervention:~1. Contextual Adaptation: Participants practice ophthalmic examination procedures in a simulated clinical environment to familiarize themselves with real-world conditions.~2. Behavioral Strategies: Positive reinforcement, such as rewards (snacks, toys, or videos), is used to encourage participation and cooperation during sessions.~3. Cognitive Support: Animated materials and interactive exercises are employed to teach the concepts required for visual tests, with take-home tasks for generalization.~4. Individualized Goals: Individualized training plans and objectives are established collaboratively with caregivers based on participants' cognitive and behavioral profiles.~Duration and Frequency:~Six sessions, each lasting one hour, are conducted biweekly, with flexibility based on caregiver availability.
Study: NCT06718439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restrictive Transfusion
Description: Red blood cell transfusion when the participant's hemoglobin level is measured below 70 g/L or to maintain a hemoglobin target range of 70-80 g/L. This strategy will be adhered to during surgery and up to 6 hours in the post-operative anesthesia care unit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liberal transfusion
Description: Red blood cell transfusion when the participant's hemoglobin level is measured below 90 g/L or to maintain a hemoglobin target range of 90-100 g/L. This strategy will be adhered to during surgery and up to 6 hours in the post-operative anesthesia care unit.
Study: NCT06712680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product HYP-6589
Description: HYP-6589 should be administered orally at the recommended dosage
Study: NCT06719167

Intervention type: BEHAVIORAL
Intervention: Psychoterapy
Description: During 11 weeks admission the programme will include group sessions using different modalities (psychoeducation videos, live psychoeducation groups, expressive arts therapy, equine facilitated therapy, mindfulness and discussion groups) all using TIST methodology. Parallell individual therapy with therapist (psychologist or psychiatrist) and milieu therapist. All therapists will be trained minimum in TIST level 1 and recieve supervision from an expert TIST therapist.
Study: NCT06716515

Intervention type: DEVICE
Intervention: digital inclinometer
Description: Digital inclinometer to assess gender difference in knee repositioning error

Intervention type: DEVICE
Intervention: digital inclinometer
Description: Digital inclinometer to assess gender difference in knee repositioning error
Study: NCT06716775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor treating felds (TTF)
Description: Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Standard of Care
Description: Patients will be treated with the best known standard of care for NSCLC brain metastasis and undergo SRS alone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Standard of Care
Description: Patients will be treated with the best known standard of care for NSCLC brain metastasis and undergo SRS alone.
Study: NCT06715592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomicina
Description: Colposcopically guided ECT following intralesional administration / intravenous Bleomycin or intralesional Cisplatin according to ESOPE recommendations. Reassessment after 30 days by colposcopy and conization with acquisition of histological examination.
Study: NCT05498584

Intervention type: BEHAVIORAL
Intervention: exercise based cardiac rehabilitation
Description: The types of exercise are treadmill walking/walking-jogging/jogging, ergometer cycling, stair climbing, or elliptical machine training. The training intensity is gradually increased fortnightly to reach the targeted Borg's rate of perceived exertion (RPE) of 12-14. The training duration is 40 minutes, which included 5-10 minutes of warm-up and cool-down exercises. The training frequency is three sessions per week, with 36 sessions concluding a complete course.
Study: NCT05446714

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CH 4 band
Description: expansion of maxilla and observation improvement of the air way

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HH 2 bands
Description: expansion of maxilla and observation improvement of the air way

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MSE 2 bands and 4
Description: expansion of maxilla and observation improvement of the air way
Study: NCT05916300

Intervention type: OTHER
Intervention: Diagnostic ultrasonography-guided physiotherapy group
Description: All participants will complete free 10 outpatient 30-minute sessions. The therapy will be focused on increasing the range of motion and muscle strength, optimizing the function of the lower limbs, reducing possible complications of post-traumatic conditions in the ankle area.~The physiotherapy procedures of the intervention group will be modified based on the initial diagnostic ultrasonography examination.

Intervention type: OTHER
Intervention: Diagnostic ultrasonography-guided physiotherapy group
Description: All participants will complete free 10 outpatient 30-minute sessions. The therapy will be focused on increasing the range of motion and muscle strength, optimizing the function of the lower limbs, reducing possible complications of post-traumatic conditions in the ankle area.~The physiotherapy procedures of the intervention group will be modified based on the initial diagnostic ultrasonography examination.